Literature DB >> 25277085

Association of filaggrin variants with asthma and rhinitis: is eczema or allergic sensitization status an effect modifier?

Ali H Ziyab1, Wilfried Karmaus, Hongmei Zhang, John W Holloway, Susan E Steck, Susan Ewart, Syed Hasan Arshad.   

Abstract

BACKGROUND: Associations of variants of the filaggrin gene, i.e. FLG with asthma and rhinitis have been shown to be modulated by eczema status. However, it is unknown whether allergic sensitization status modifies this association. The aim of this study was to determine whether FLG variants need eczema and/or allergic sensitization as a necessary component to execute adverse effects on coexisting and subsequent asthma and rhinitis.
METHODS: In the Isle of Wight birth cohort, repeated measurements of asthma, rhinitis, eczema and allergic sensitization (documented by skin-prick tests) were taken in 1,456 children at the ages of 1, 2, 4, 10 and 18 years. Filaggrin haploinsufficiency was defined as having at least the minor allele of R501X, 2282del4 or S3247X variants. log-binomial regression models were used to test associations and statistical interactions.
RESULTS: FLG variants increased the risk of asthma [risk ratio (RR) 1.39, 95% confidence interval (CI) 1.06-1.80] and rhinitis (RR 1.37, 95% CI 1.16-1.63). In the delayed-effects models, 'FLG variants plus allergic sensitization' and 'FLG variants plus eczema' increased the risk of subsequent asthma by 4.93-fold (95% CI 3.61-6.71) and 3.33-fold (95% CI 2.45-4.51), respectively, during the first 18 years of life. In contrast, neither eczema nor allergic sensitization in combination with FLG variants increased the risk of later rhinitis.
CONCLUSIONS: Allergic sensitization and eczema modulated the association between FLG variants and asthma but not rhinitis. Our results imply that the mechanisms and pathways through which FLG variants predispose to an increased risk of asthma and rhinitis may be different.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25277085      PMCID: PMC4281035          DOI: 10.1159/000365990

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  27 in total

Review 1.  Filaggrin mutations associated with skin and allergic diseases.

Authors:  Alan D Irvine; W H Irwin McLean; Donald Y M Leung
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

Review 2.  The role of filaggrin in the atopic diathesis.

Authors:  G M O'Regan; A D Irvine
Journal:  Clin Exp Allergy       Date:  2010-07       Impact factor: 5.018

Review 3.  Filaggrin mutations and atopy: consequences for future therapeutics.

Authors:  Jennifer Heimall; Jonathan M Spergel
Journal:  Expert Rev Clin Immunol       Date:  2012-02       Impact factor: 4.473

Review 4.  The role of allergy in disease.

Authors:  William W Busse
Journal:  Immunol Rev       Date:  2011-07       Impact factor: 12.988

5.  Filaggrin gene mutations are associated with independent atopic asthma in Chinese patients.

Authors:  M Li; X Chen; R Chen; Y Bao; Z Yao
Journal:  Allergy       Date:  2011-09-19       Impact factor: 13.146

6.  The influence of gender and atopy on the natural history of rhinitis in the first 18 years of life.

Authors:  R J Kurukulaaratchy; W Karmaus; A Raza; S Matthews; G Roberts; S H Arshad
Journal:  Clin Exp Allergy       Date:  2011-06       Impact factor: 5.018

7.  Trends in eczema in the first 18 years of life: results from the Isle of Wight 1989 birth cohort study.

Authors:  A H Ziyab; A Raza; W Karmaus; N Tongue; H Zhang; S Matthews; S H Arshad; G Roberts
Journal:  Clin Exp Allergy       Date:  2010-12       Impact factor: 5.018

8.  Interplay of filaggrin loss-of-function variants, allergic sensitization, and eczema in a longitudinal study covering infancy to 18 years of age.

Authors:  Ali H Ziyab; Wilfried Karmaus; Mitra Yousefi; Susan Ewart; Eric Schauberger; John W Holloway; Hongmei Zhang; Syed Hasan Arshad
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

Review 9.  One remarkable molecule: filaggrin.

Authors:  Sara J Brown; W H Irwin McLean
Journal:  J Invest Dermatol       Date:  2011-12-08       Impact factor: 8.551

10.  Epidemiologic methods of assessing asthma and wheezing episodes in longitudinal studies: measures of change and stability.

Authors:  Nelís Soto-Ramírez; Ali H Ziyab; Wilfried Karmaus; Hongmei Zhang; Ramesh J Kurukulaaratchy; Susan Ewart; Syed Hasan Arshad
Journal:  J Epidemiol       Date:  2013-08-31       Impact factor: 3.211

View more
  6 in total

1.  Cohort Profile: The Isle Of Wight Whole Population Birth Cohort (IOWBC).

Authors:  S Hasan Arshad; John W Holloway; Wilfried Karmaus; Hongmei Zhang; Susan Ewart; Linda Mansfield; Sharon Matthews; Claire Hodgekiss; Graham Roberts; Ramesh Kurukulaaratchy
Journal:  Int J Epidemiol       Date:  2018-08-01       Impact factor: 7.196

Review 2.  Disease trajectories in childhood atopic dermatitis: an update and practitioner's guide.

Authors:  A D Irvine; P Mina-Osorio
Journal:  Br J Dermatol       Date:  2019-05-15       Impact factor: 9.302

3.  History of allergic rhinitis and risk of asthma; a systematic review and meta-analysis.

Authors:  Hamid Reza Tohidinik; Narmeen Mallah; Bahi Takkouche
Journal:  World Allergy Organ J       Date:  2019-10-17       Impact factor: 4.084

4.  Association of Asthma and Rhinitis with Epigenetics of Coronavirus Related Genes.

Authors:  Aniruddha Rathod; Rutu Rathod; Hongmei Zhang; Parnian Kheirkhah Rahimabad; Wilfried Karmaus; Hasan Arshad
Journal:  Epigenet Insights       Date:  2021-09-29

5.  DNA Methylation and Asthma Acquisition during Adolescence and Post-Adolescence, an Epigenome-Wide Longitudinal Study.

Authors:  Aniruddha Rathod; Hongmei Zhang; Syed Hasan Arshad; Susan Ewart; Caroline L Relton; Wilfried Karmaus; John W Holloway
Journal:  J Pers Med       Date:  2022-02-02

Review 6.  Genetic Mechanisms of Asthma and the Implications for Drug Repositioning.

Authors:  Yue Huo; Hong-Yu Zhang
Journal:  Genes (Basel)       Date:  2018-05-03       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.